Panitumumab: The evidence for its use in the treatment of metastatic colorectal cancer

Core Evidence

Volumn 5, Issue , 2010, Pages 61-76

  Berardi, Rossana ^a   Onofri, Azzurra ^a   Pistelli, Mirco ^a   Maccaroni, Elena ^a   Scartozzi, Mario ^a   Pierantoni, Chiara ^a   Cascinu, Stefano ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Colorectal cancer; EGFR; K RAS; Panitumumab

Indexed keywords

AMPHIREGULIN; ANTINEOPLASTIC AGENT; B RAF KINASE; BEVACIZUMAB; CETUXIMAB; CYCLOSPORIN; EPIREGULIN; ERLOTINIB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; OXALIPLATIN; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B;

ADVANCED CANCER; ANUS CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CHEILITIS; CHROMOSOME 7; COLORECTAL CANCER; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DISEASE FREE INTERVAL; DISEASE SEVERITY; DRUG COST; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; ESOPHAGUS CANCER; EYE TOXICITY; GENE DOSAGE; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; HAIR DISEASE; HUMAN; HYPOMAGNESEMIA; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INFECTION; KIDNEY CANCER; LUNG CANCER; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; PANCREAS CANCER; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; SKIN MANIFESTATION; SKIN TOXICITY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WILD TYPE;

EID: 79959298055     PISSN: 15551741     EISSN: None     Source Type: Journal    
DOI: 10.2147/CE.S7035     Document Type: Review

References (87)

1. Overman MJ, Hoff PM. EGFR-targeted therapies in colorectal cancer. Dis Colon Rectum. 2007;50:1259-1270. (Pubitemid 47087472)
2. Mayer A, Takimoto M, Fritz E, et al. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer. 1993;71:2454-2460. (Pubitemid 23100476)
3. Giusti RM, Shastri KA, Cohen MH, et al. FDA drug approval summary: panitumumab (Vectibix). Oncologist. 2007;12:577-583. (Pubitemid 350012121)
4. Hoy SM, Wagstaff AJ. Panitumumab: in the treatment of metastatic colorectal cancer. Drugs. 2006;66:2005-2014. (Pubitemid 44771939)
5. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol. 2005;23:2445-2459. (Pubitemid 47050835)
6. Yang XD, Jia XC, Corvalan JR, et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol. 2001;38:17923.
7. Foon KA, Yang XD, Weiner LM, et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys. 2004;58:984-990. (Pubitemid 38221160)
8. Ranson M. Technology evaluation: ABX-EGF, Abgenix/Amgen. Curr Opin Mol Ther. 2003;5:541-546.
9. Carteni G, Fiorentino R, Vecchione L, et al. Panitumumab a novel drug in cancer treatment. Ann Oncol. 2007;18 Suppl 6:vi16-vi21.
10. Pfeiffer P, Qvortrup C, Eriksen JG. Current role of antibody therapy in patients with metastatic colorectal cancer. Oncogene. 2007;26:3661-3678. (Pubitemid 46842711)
11. Rowinsky EK, Schwartz GH, Gollob JA, et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol. 2004;22:3003-3015. (Pubitemid 41103711)
12. Figlin RA, Belldegrun AS, Crawford J, et al. ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with advanced cancer: phase 1 clinical results. Proc Am Soc Clin Oncol. 2002;Abstr 35.
13. Weiner L, Belldegrun A, Rowinsky E, et al. Update results from a dose and schedule study of panitumumab (ABX-EGF) monotherapy, in patients with advanced solid malignancies. J Clin Oncol. 2005;23:16S (abstract 3059).
14. Malik I, Hecht JR, Patnaik A, et al. Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC) (abstract). Proc ASCO. 2005;23:3520.
15. Berlin J, Neubauer M, Swanson P, et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing ≥10% epidermal growth factor receptor (EGFr) (abstract). Proc ASCO. 2006;24:3548.
16. Hecht J, Mitchell E, Baranda J, Richards D, et al. Panitumumab (pmab) efficacy in patients (pts) with metastatic colorectal cancer (mCRC) with low or undetectable levels of epidermal growth factor receptor (EGFr): final efficacy and KRAS analyses. ASCO Gastrointestinal Cancers Symposium. Orlando, USA: 2008.
17. Hecht J, Posey J, Tchekmedyian S, et al. Panitumumab in combination with 5-fluorouracil, leucovorin, and irinotecan (IFL) or FOLFIRI for firstline treatment of metastatic colorectal cancer (mCRC). ASCO Gastrointestinal Cancers Symposium. San Francisco, USA: 2006. Abstr. 237.
18. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared withbest supportive care alone in patients with chemotherapy refractory metastatic colorectal cancer. J Clin Oncol. 2007;25:1658-1664. (Pubitemid 46797944)
19. Van Cutsem E, Siena S, Humblet Y, et al. An open-label single arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol. 2008;19:92-98.
20. Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase III of chemotherapy, bevacizumab, and panitumumab a compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009;27:672-680.
21. Douillard J, Siena S, Cassidy J, et al. Randomized phase III study of panitumumab with FOLFOX4 compared to FOLFOX4 alone as 1st-line treatment (tx) for metastatic colorectal cancer (mCRC): the PRIME trial. Joint ECCO/ESMO Multidisciplinary Congress. Berlin: 2009; Abstr. 10-LBA.
22. Peeters M, Price T, Hotko Y, et al. Randomized phase III study of panitumumab with FOLFIRI vs FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC). Joint ECCO/ESMO Multidisciplinary Congress. Berlin: 2009. Abstr. 14-LBA.
23. http://www.cancer.gov/clinicaltrials/search
24. Meropol NJ, Berlin J, Hecht JR, et al. Multicenter study of ABX-EGF monotherapy in patients with metastatic colorectal cancer. Proc ASCO. 2003;Abstr. 1026.
25. Hecht JR, Patnaik A, Malik I, et al. ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): An updated analysis. Proc ASCO. 2004;Abstr. 3511.
26. Francoual M, Etienne-Grimaldi MC, Formento JL, et al. EGFR in colorectal cancer: more than a simple receptor. Ann Oncol. 2006;17(6):962-967 (Pubitemid 43778987)
27. Personeni N, Hendlisz A, Gallez J, et al. Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer. Semin Oncol. 2005;32(6):S59-S62. (Pubitemid 43080918)
28. Khambata-Ford S, Garret C, Meropol N, et al. Expression of epiregulin and amphiregulin and KRAS mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol. 2007;25:3230-3237. (Pubitemid 47325606)
29. Janne PA, Engelman JA, Johnson BE. Epidermal growth factor receptor mutations in nonsmall-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol. 2005;23:3227-3234. (Pubitemid 46211347)
30. Tsuchihashi Z, Khambata-Frd S, Hanna N, et al. Responsiveness to cetuximab without mutations in EGFR. N Engl J Med. 2005;353:208-209. (Pubitemid 41058356)
31. Moroni M, Veronese S, Benevenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti-EGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 2005;6:279-286. (Pubitemid 40590264)
32. Moroni M, Sartore-Bianchi A, Benvenuti S, et al. Somatic mutation of EGFR catalytic domain and treatment with gefitinib in colorectal cancer. Ann Oncol. 2005;16(11):1848-1849. (Pubitemid 41631254)
33. Press OA, Zhang W, Gordon MA, et al. Gender-related survival differences associated with EGFR polymorphisms in metastatic colon cancer. Cancer Res. 2008;68(8):3037-3042. (Pubitemid 351556305)
34. Goncalves A, Esteyries S, Taylor-Smedra B, et al. A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment. BMC Cancer. 2008;8:1-11
35. Graziano F, Ruzzo A, Loupakis F, et al. Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. J Clin Oncol. 2008;26(9):1427-1434.
36. Wang WS, Chen PM, Chiou TJ, et al. Epidermal growth factor receptor R497K polymorphism is a favorable prognostic factor for patients with colorectal carcinoma. Clin Cancer Res. 2007;13(12):3597-3604.
37. Garm Spindler KL, Pallisgaard N, Rasmussen AA , et al. The importance of KRAS mutations and EGF61A > G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer. Ann Oncol. 2009;20(5):879-884.
38. Zhang W, Gordon M, Press OA, et al. Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with cetuximab. Pharmacogenet Genomics. 2006;16(7):475-483. (Pubitemid 43922345)
39. Carcereny E, Castellvi-Bel S, Alonso V, et al. EGFR polymorphisms as predictors of clinical outcome in patients with advanced colorectal cancer treated with cetuximab and panitumumab. J Clin Oncol. 2008;26s:Abstr. 4124.
40. Maurel J, Alonso-Espinaco V, Alonso V, et al. EGFR polymorphism and KRAS mutational status as predictors of resistance to anti-EGFR therapy in advanced colorectal cancer (ACRC): A GEMCAD study. J Clin Oncol. 2009;26:Abstr. 4060.
41. Shia J, Klimstra DS, Li AR, et al. Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study. Mod Pathol. 2005;18(10):1350-1356. (Pubitemid 41348654)
42. Lievre A, Bachet JB, Le Corre D, et al. K-RAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66(8):3992-3995.
43. Personeni N, Fieuws S, Piessevaux H, et al. Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study. Clin Cancer Res. 2008;14(18):5869-5876.
44. Capuzzo F, Finocchiaro G, Rossi E, et al. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol. 2008;19:717-723. (Pubitemid 351461042)
45. Capuzzo F, Varela-Garcia M, Finocchiaro G, et al. Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. Br J Cancer. 2008;99:83-89. (Pubitemid 351920237)
46. Goncalvez A, Esteyries S, Taylor-Smedra B, et al. A polymorphism of EGFR domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab based treatment. BMJ Cancer. 2008;8:169.
47. Frattini M, Saletti P, Romagnani E, et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer. 2007;97:1139-1145. (Pubitemid 47587019)
48. Lenz HJ, Van Cutsem E, Khambata-Ford S, et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluoropyrimidines. J Clin Oncol. 2006;24:4914-4921. (Pubitemid 46630920)
49. Khambata-Ford S, Garret C, Meropol N, et al. Expression of epiregulin and amphiregulin and KRAS mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol. 2007;25:3230-3237. (Pubitemid 47325606)
50. Sartore-Bianchi A, Moroni M, Veronese S, et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol. 2007;25(22):3238-3245. (Pubitemid 47325607)
51. Tejpar S, De Roock W, Biesmans B, et al. High amphiregulin and epiregulin expression in KRAS wild type colorectal primaries predicts response and survival benefit after treatment with cetuximab and irinotecan for metastatic disease. ASCO Gastrointestinal Cancers Symposium. 2008:Abstr. 411.
52. Baker JB, Dutta D, Watson T, et al. Evaluation of tumor gene expression and KRAS mutations in FFPE tumor tissue as predictors of response to cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008;26s:A3512
53. Jonker DJ, Karapetis C, Harbison C, et al. High epiregulin (EREG) gene expression plus K-ras wild-type (WT) status as predictors of cetuximab benefit in the treatment of advanced colorectal cancer (ACRC): Results from NCIC CTG CO.17-A phase III trial of cetuximab versus best supportive care (BSC). J Clin Oncol. 2009;26:Abstr. 4016.
54. Adams R, Maughan T. Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer. Expert Rev Anticancer Ther. 2007;7:503-518. (Pubitemid 46681806)
55. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 2007;67(6):2643-2648. (Pubitemid 46548951)
56. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(10):1626-1634.
57. Freeman DJ, Juan T, Reiner M. Association of K-RAS mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin Colorectal Cancer. 2008;7(3):184-190.
58. Cohn AL, Smith DA, Neubauer MA, et al. Results from panitumumab (pmab) regimen evaluation in colorectal cancer to estimate primary response to treatment (PRECEPT): Second-line treatment with pmab and FOLFIRI by tumor KRAS status. J Clin Oncol. 2009;26:Abstr. 4067.
59. Kohne CH, Mineur L, Greil R, et al. Primary analysis of a phase II study (20060314) combining first-line panitumumab with FOLFIRI in the treatment of patients with metastatic colorectal cancer. ASCO Gastro-Intestinal Symposium. Orlando, US: 2010.
60. Barault L, Veyrie N, Jooste V, et al. Mutations in the RAS-MAPK, PI(3) K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer. 2008;122:2255-2259.
61. Tan YH, Liu Y, Eu KW, et al. Detection of B-RAF V600E mutation by pyrosequencing. Pathology. 2008;40:295-298. (Pubitemid 351563933)
62. Calistri D, Rengucci C, Seymour I, et al. Mutation analysis of p53, KRAS and B-RAF genes in colorectal cancer progression. J Cell Physiol. 2005;204:484-488. (Pubitemid 40934643)
63. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type B-RAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008;26:5705-5712.
64. Vehlo S, Oliveira C, Ferreira A, et al. The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer. 2005;41:1649-1654. (Pubitemid 40981849)
65. Samuels Y, Diaz LA Jr, Schmidt-Kittler O, et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell. 2005;7:561-573. (Pubitemid 40799249)
66. Blanco-Aparicio C, Renner O, Leal J, Carnero A. PTEN, more than the AKT pathway. Carcinogenesis. 2007;28:1379-1386. (Pubitemid 47243536)
67. Carnero A, Blanco-Aparicio C, Renner O, et al. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets. 2008;8:187-198. (Pubitemid 351688437)
68. Perrone F, Lampis A, Orsenigo M, et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol. 2009;20:84-90.
69. Loupakis F, Pollina L, Stasi I, et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol. 2009;27(16):2622-2629.
70. Bardier A, Golmard J, Domont J, et al. Coexpression of EGFR, pEGFR, VEGF, pVEGF, PTEN, pAKT and p21 in colorectal cancer patients can have IHC variability between metastases and primary tumors and for EGFR.targeted therapies, p21 and VEGF appear reliably as predictive factors of response. J Clin Oncol. 2008;26s:A22074.
71. Frattini M, Saletti P, Romagnani E, et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer. 2007;97:1139-1145. (Pubitemid 47587019)
72. Sartore-Bianchi A, Martini M, Molinari F, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res. 2009;69:1851-1857.
73. Finocchiaro G, Cappuzzo F, Janne PA, et al. EGFR, HER2 and Kras as predictive factors for cetuximab sensitivity in colorectal cancer. J Clin Oncol. 2007;25(l):Abstr. 4021.
74. Scartozzi M, Bearzi I, Mandolesi A, et al. Correlation of insulin-like growth factor 1 (IGF-1) expression and clinical outcome in K-RAS wild-type colorectal cancer patients treated with cetuximab-irinotecan. J Clin Oncol. 2009;26:Abstr. 4017.
75. Wheeler DL, Huang S, Kruser TJ, et al. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene. 2008;27(28):3944- 3956. (Pubitemid 351913636)
76. Zhang W, Gordon M, Press OA, et al. Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with cetuximab. Pharmacogenet Genomics. 2006;16(7):475-483. (Pubitemid 43922345)
77. Vallböhmer D, Zhang W, Gordon M, et al. Molecular determinants of cetuximab efficacy. J Clin Oncol. 2005;23(15):3536-3544
78. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007;25(13):1658-1664. (Pubitemid 46797944)
79. Peeters M, Siena S, Van Cutsem E, et al. Association of progression-free survival , overall survival and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer. 2009;115:1544-1554.
80. Berlin J, Van Cutsem E, Peeters M, et al. Predictive value of skin toxicity severity for response to panitumumab in patients with metastatic colorectal cancer (mCRC): a pooled analysis of five clinical trials. J Clin Oncol. 2007;25(18S):Abstr. 4134.
81. Schrag D. The price tag on progress - chemotherapy for colorectal cancer. N Engl J Med. 2004;351:317-319. (Pubitemid 38944397)
82. Paramore LC, Thomas SK, Knopf KB, et al. Estimating costs of care for patients with newly diagnosed metastatic colorectal cancer. Clin Colorectal Cancer. 2006;6:52-58.
83. Bracco A, Farrimond BJ, Fitzgibbon JW, et al. A model to demonstrate the comparative costs between panitumumab and cetuximab for third-line metastatic colorectal cancer patients in Italy. ISPOR Annual European Congress. 2008;Athens, Greece.
84. Tappenden P, Jones R, Paisley S, Carroll C. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Health Technol Assess. 2007;11:1-128.
85. Norum J. Cetuximab in the treatment of metastatic colorectal cancer: a model-based cost-effectiveness analysis. J Chemother. 2006;18:532-537.
86. Van Cutsem E, Lang I, D'haens G, et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. J Clin Oncol. 2008;26:Abstr. 2.
87. Mancl EE, Kolesar JM, Vermeulen LC. Clinical and economic value of screening for Kras mutations as predictors of response to epidermal growth factor receptor inhibitors. Am J Health Syst Pharm. 2009;66(23):2105-2112.